REGENXBIO to Host Webcast Discussing Interim Functional Data from the Phase I/II AFFINITY DUCHENNE庐 Trial of RGX-202
- None.
- None.
- Event will feature Aravindhan Veerapandiyan, M.D., principal investigator of the AFFINITY DUCHENNE庐 trial
Webcast details
Title:听AFFINITY DUCHENNE庐 Trial of RGX-202: Phase I/II Interim Functional Data
Date/Time: Thursday, June 5, 2025, at 8:00 a.m. EDT听
Access:听The live webcast can be accessed 听and in the Investors section of REGENXBIO's website at . An archived replay of the webcast will be available for approximately 30 days following the presentation.
ABOUT REGENXBIO Inc.
REGENXBIO is a biotechnology company on a mission to improve lives through the curative potential of gene therapy. Since its founding in 2009, REGENXBIO has pioneered the field of AAV gene therapy. REGENXBIO is advancing a late-stage pipeline of one-time treatments for rare and retinal diseases, including RGX-202 for the treatment of Duchenne; clemidsogene lanparvovec (RGX-121) for the treatment of MPS II and RGX-111 for the treatment of MPS I, both in partnership with Nippon Shinyaku; and surabgene lomparvovec (ABBV-RGX-314) for the treatment of wet AMD and diabetic retinopathy, in collaboration with AbbVie. Thousands of patients have been treated with REGENXBIO's AAV platform, including those receiving Novartis' ZOLGENSMA庐. REGENXBIO's investigational gene therapies have the potential to change the way healthcare is delivered for millions of people. For more information, please visit .
Contacts:
Dana Cormack
Corporate Communications
[email protected]听
Investors:
George E. MacDougall
Investor Relations
[email protected]
听
View original content to download multimedia:
SOURCE REGENXBIO Inc.
FAQ
When will REGENXBIO (RGNX) present the AFFINITY DUCHENNE trial data?
What is RGX-202 being developed for by REGENXBIO?
Who is the principal investigator of the AFFINITY DUCHENNE trial?
How can investors access REGENXBIO's AFFINITY DUCHENNE trial data presentation?
